



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

To

Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

To

BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai - 400001

Date: October 13, 2026

Symbol: BALPHARMA

Scrip Code: 524824

Sub: Dividend Payment Update - Intimation regarding disbursement of final dividend for the FY 2025-26 and withholding of dividend in respect of shareholders with incomplete KYC/bank details or invalid, blocked or closed bank accounts

***Reference:** Regulations 30 and 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the applicable SEBI circulars, including the circular dated November 3, 2021, as subsequently amended, and the applicable Master Circulars for Registrars to an Issue and Share Transfer Agents.*

Dear Sir/Madam,

We wish to inform you that the Members of Bal Pharma Limited ("the Company"), at their 39th Annual General Meeting held on Thursday, September 24, 2026, approved a final dividend of ₹1.20 per equity share of ₹10 each for the financial year 2025-26.

The Company has deposited the declared dividend amount into its designated bank account within the prescribed timeline and has completed the disbursement of the final dividend on October 9, 2026, to eligible shareholders whose names appeared in the Register of Members or the records of the Depositories as on the record date, i.e., September 17, 2026. The dividend was remitted through electronic modes, including NACH/NECS/direct bank remittance, wherever valid bank account details were available.

Shareholders are requested to verify the credit of the final dividend in their respective bank accounts. They are also advised to check their Form 26AS/AIS or the Income Tax e-filing portal, as applicable, for details of tax deducted at source ("TDS") on the dividend, wherever applicable.

Further, the dividend amounts pertaining to shares already transferred to the Investor Education and Protection Fund ("IEPF") account will be duly transferred to the prescribed IEPF account in accordance with the applicable provisions of the Companies Act, 2013, and the IEPF Rules. The details of such transfers will also be available on the Company's website for the information of the shareholders.

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

 www.balpharma.com



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

Withholding of Dividend: Shareholders Holding Shares in Physical Form

The dividend payable to physical shareholders whose mandatory KYC details and/or bank account particulars are incomplete or have not been updated with the Registrar and Transfer Agent ("RTA") has been withheld in accordance with the applicable SEBI circulars and guidelines.

The dividend amounts that could not be disbursed have been deposited into the Company's bank account designated for this purpose. The amounts remaining unpaid after the expiry of 30 days from the date of declaration of the dividend shall be transferred to the Company's Unpaid Dividend Account within the statutory period, in accordance with Section 124 of the Companies Act, 2013, and the applicable rules.

KYC updation and release of withheld dividend

Physical shareholders are requested to update their KYC and bank account details by submitting the applicable forms and supporting documents to the Company's RTA, MUFG Intime India Private Limited (Unit: Bal Pharma Limited).

The applicable forms are as follows:

Form ISR-1	For Updation KYC details ie PAN, Address, Bank Particulars, Mobile No. Email ID etc alongwith self attested Aadhar card, PAN card copy, Client Master List (CML) if having demat account. (If shares are in joint name, PAN/Aadhar are required for all joint shareholders).
Form ISR-2	For banker attestation of Signature along with Original Cancelled Cheque with your name(s) printed thereon or self-attested copy of bank passbook/statement.
Form ISR-3	For " Opt-out the Nomination, if nomination is not required.
Form SH-13	For Updation of Nomination.

For release of withheld dividend for FY 2025-26 and previous financial years, shareholders are requested to submit Forms ISR-1 and ISR-2, along with the requisite supporting documents, as applicable.

The prescribed forms can be downloaded from the RTA's website:

<https://web.in.mpms.mufg.com/KYC-downloads.html>

Address for Submission of KYC documents

Registrar and Transfer Agent:
MUFG Intime India Private Limited
(Unit: Bal Pharma Limited)
C-101, Embassy 247, L.B.S. Marg,
Vikhroli (West), Mumbai – 400083.

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

 www.balpharma.com



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

Shareholders are requested to mention "Bal Pharma Limited" as the unit while submitting their documents.

Email ID for submission of scanned KYC documents: kyc@in.mpms.mufig.com

Copy to: investors@balpharma.com

Withholding of Dividend: Shareholders Holding Shares in Dematerialised Form

Shareholders holding shares in dematerialised form whose dividend could not be credited due to invalid bank account details or bank accounts that are blocked or closed are requested to update their bank account details with their respective Depository Participant ("DP").

Upon updating the bank account details, shareholders are advised to contact their DP and, where necessary, inform the Company and/or the RTA so that the updated particulars can be appropriately reflected in the relevant records and the dividend payment can be processed, subject to applicable procedures.

The Company is taking necessary steps to facilitate the release of withheld dividend upon receipt and verification of the requisite KYC and bank account documents from the concerned shareholders.

Contact Details for Investor Queries

Shareholders requiring any clarification or assistance regarding KYC updation or dividend payments may contact the Company or its RTA using the below details.

Contact details	Company	RTA
Email ID	investors@balpharma.com	investor.helpdesk@in.mpms.mufig.com
Website	www.balpharma.com	www.in.mpms.mufig.com

This intimation is being provided for the information of the Stock Exchanges and the shareholders.

Please take this intimation on your records

Thanking You.

For Bal Pharma Limited

**Shreepada
M L**

Digitally signed by Shreepada M L
DN: c=IN, o=Personal, title=2962,
pseudonym=aa433d36a7b1477bb9a1a9af3ce8c174,
2.5.4.20=d4eb6b0c7d0586c2cf2ea033303d29e037a5365
ca2769a0f737d628a81f34ef, postalCode=577452,
st=Karnataka,
serialNumber=806f0c2a9f8445a728f619cf25229b275289
60b837882f0da36b87703d5b5a02, cn=Shreepada M L
Date: 2026.10.13 11:45:27 +05'30'



Shreepada ML

Company Secretary and Compliance officer

ICSI M No : A66681

Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA.

Ph: +91 80 41570811/813.

CIN # L85110KA1987PLC008368

www.balpharma.com